{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:51:01Z","timestamp":1794559861082,"version":"4.9.1"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To review the efficacy, safety, and tolerability of a sublingual formulation of cyclobenzaprine for the treatment of fibromyalgia.\n                    <jats:bold>Data Sources:<\/jats:bold>\n                    A literature search was conducted through PubMed and DrugBank using the following terms: cyclobenzaprine, fibromyalgia, sublingual, Tonmya\n                    <jats:sup>TM<\/jats:sup>\n                    , and TNX-102 SL.\n                    <jats:bold>Study Selection and Data Extraction:<\/jats:bold>\n                    Articles describing the pharmacology, pharmacokinetics, efficacy, safety, and\/or tolerability of sublingual cyclobenzaprine were included in this review.\n                    <jats:bold>Data Synthesis:<\/jats:bold>\n                    Cyclobenzaprine is a tricyclic antidepressant like agent which exhibits sedative and muscle relaxant effects in the treatment of fibromyalgia. Clinical trials have demonstrated improvements in daily pain scores compared with placebo. Common adverse events associated with this agent include oral hypoesthesia, oral paresthesia, and abnormal taste.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Pharmacologic agents receive a weak recommendation for use in the treatment guidelines and include agents such as duloxetine, pregabalin, tramadol, amitriptyline, and a nonsublingual formulation of cyclobenzaprine. Tonmya, the newest agent approved for fibromyalgia, provides clinicians with an additional treatment option in a convenient dosage form for this potentially debilitating condition.\n                  <\/jats:p>","DOI":"10.1177\/87551225261426559","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:46:17Z","timestamp":1773240377000},"page":"143-148","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya\n                    <sup>TM<\/sup>\n                    for Fibromyalgia"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-2906","authenticated-orcid":false,"given":"Erin","family":"St. Onge","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc (Tyler)","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haven","family":"Rogers","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Guerrero","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2157-9037","authenticated-orcid":false,"given":"Bradley","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"American College of Rheumatology. Fibromyalgia. Accessed October 22 2025. https:\/\/rheumatology.org\/patients\/fibromyalgia"},{"key":"e_1_3_2_3_2","unstructured":"National Fibromyalgia Association. Fibromyalgia prevalence. Accessed October 22 2025. https:\/\/www.fmaware.org\/fibromyalgia-prevalence\/"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202003030"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20076"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110194"},{"key":"e_1_3_2_9_2","unstructured":"Tonix Pharmaceuticals Inc. Tonmya package insert. 2025. Accessed October 19 2025. https:\/\/www.tonixpharma.com\/wp-content\/uploads\/2025\/08\/Tonmya-Prescribing-Information.pdf"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25142"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaf089"},{"key":"e_1_3_2_12_2","unstructured":"Tonix Pharmaceuticals. Tonix Pharmaceuticals announces FDA approval of Tonmya\u2122 (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia. Globe Newswire. August 15 2025. Accessed December 5 2025. https:\/\/ir.tonixpharma.com\/news-events\/press-releases\/detail\/1585\/tonix-pharmaceuticals-announces-fda-approval-of"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"key":"e_1_3_2_14_2","unstructured":"DrugBank Online. Cyclobenzaprine (DB00924)\u2013BioInteractions. DrugBank. Accessed February 17 2025. https:\/\/go.drugbank.com\/drugs\/DB00924\/biointeractions"},{"key":"e_1_3_2_15_2","unstructured":"Eli Lilly and Company. Cymbalta package insert. 2004. Accessed December 2 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022516lbl.pdf"},{"key":"e_1_3_2_16_2","unstructured":"Pfizer. Lyrica package insert. 2018. Accessed December 2 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021446s035022488s013lbl.pdf"},{"key":"e_1_3_2_17_2","unstructured":"Sandoz Inc. Amitriptyline package insert. Revised 2025. Accessed December 2 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/085968s112lbl.pdf"},{"key":"e_1_3_2_18_2","unstructured":"Janssen Ortho LLC. Ultram package insert. Revised 2008. Accessed January 28 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020281s032s033lbl.pdf"},{"key":"e_1_3_2_19_2","unstructured":"GoodRx.com. Tonmya. GoodRx website. Accessed December 1 2025. https:\/\/www.goodrx.com\/tonmya?srsltid=AfmBOorAV-jooJW9QgYavhtZR7WVzx4veBsYwEnVEnRyHGnQ36rok0Sj"},{"key":"e_1_3_2_20_2","unstructured":"GoodRx.com. Fibromyalgia: your GoodRx guide. Accessed December 1 2025. https:\/\/www.goodrx.com\/conditions\/fibromyalgia"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261426559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225261426559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261426559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:44:33Z","timestamp":1778233473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225261426559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/87551225261426559"],"URL":"https:\/\/doi.org\/10.1177\/87551225261426559","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}